As the coronavirus (COVID-19) outbreak continues, we’re learning more about the disease, what it does to the body and the damage it can cause. But not sure you understand yet exactly what the virus can do to you?

           

COVID-ARDS  (ADULT RESPIRATORY DISTRESS SYNDROME)

REVIEW OF SYMPTOMS: 

– Patient orally intubated at the time of interview and examination

CHEST: Complains of increased dyspnea and cough with increased green sputurn production 2 days prior to admission.

HEART: Complains of weakness for 10 days prior to arrival.

URINARY SYSTEM: Decrease in normal urinary output because of decreased oral intake.

 

ARDS, shock lung, smoke lung, Danang lung, SIRS, sepsis.

These are terms for acute pulmonary failure where the lung is acting as a shock organ. It has been demonstrated that patients dying of respiratory failure due to COVID have histopathologic lesions consistent with ARDS. There is a cytokine storm. There are signs of septic shock and multi-system organ failure. There are no successful therapies. Check out Dr. Carol Meschter’s CBI White-Papers – Preclinical Animal Models of COVID-ARDS
                                                                                                                                                                                                                                                                 At CBI, we offer a number of ARDS type models including oleic acid-induced ARDS, LPS-induced pulmonary inflammation, albumin-induced immune mediated pulmonary inflammation, murine sarcoidiosis- Propionibacterium acne-induced hypersensitivity or granulomatous pneumonia, pulmonary hyperoxygenation, aspergillus pneumonia, murine Farmer’s Lung- Saccharopolyspora rectivirgula-induced hypersensitivity pneumonitis, cecal ligation and puncture and oxygen-induced pulmonary bronchodysplasia. All of these models offer good correlation with the lesions in COVID-induced ARDs. We offer customized and innovative pulmonary models. With our models, assessments include respiratory signs, oxygenation, cytokine assays, BAL assessment, histopathology and immunohistochemistry as part of a plan to assess the potential activity of test articles for treatment of COVID-19 ARDS.
                                                                                                                                                                                                                                                             This is an emerging, rapidly evolving situation and Comparative Biosciences, Inc. will provide updated information as it becomes available, in addition to updated guidance.
                                                                                                                                                                                                                                                              CBI HAS THE EXPERIENCE AND CAPABILITIES TO CONDUCT PRECLINICAL MODELS OF ARDS TO ASSESS POTENTIAL THERAPIES – Dr Carol Meschter
                                                                                                                                                                                                                                                 

Comparative Biosciences, Inc.    ·    Phone: 408.738.9260